Assess the Antitumor Efficacy of CAR-T Cells Using Validated Cell Line Derived Xenografts
Model selection based on expression of your CAR-T cell target is made easy through XenoBase®, our curated online database of well-characterized cell line derived xenografts, including full model genetic characterization.
In Vivo Imaging
Bioluminescent imaging (BLI) can be applied to the evaluation of orthotopic and systemic cell line derived xenograft models to assess tumor progression non-invasively, in vivo, throughout the whole study.
Our BLI capabilities facilitate the monitoring of study progression and deliver results in real time to successfully guide CAR-T cell therapy development.
Need a Highly Sensitive, Validated Model for your CD19 CAR-T Therapy Efficacy Testing?
Look no further than our Raji human Burkitt lymphoma cell line derived xenograft model.
CD19 - The Key CAR-T Therapy Target
CD19 is the key antigen targeted by CAR-T cell therapy to date, for treatment of a range of hematological malignancies e.g. chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and B cell lymphoma.
Validated preclinical models are needed to drive forward preclinical research in this fast paced area of the field. Our Raji human Burkitt lymphoma cell line derived xenograft model is:
- CD19 positive
- Highly sensitive to CAR-T CD19 targeting
- Shows validated model survival following CAR-CD19 T cell therapy
Our model is available immediately for in vivo efficacy studies.
Contact us to discuss your CAR-T therapy project needs, and to find out more on our CAR-T therapy evaluation platform.